What is Brookline Cap M’s Estimate for XFOR Q3 Earnings?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Cap M issued their Q3 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a report released on Tuesday, March 17th. Brookline Cap M analyst L. Cann expects that the company will earn ($0.27) per share for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Cap M also issued estimates for X4 Pharmaceuticals’ Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($0.96) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.85 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.14. The company had revenue of $2.57 million during the quarter, compared to the consensus estimate of $1.68 million. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%.

Several other equities research analysts also recently weighed in on XFOR. Stifel Nicolaus set a $10.00 price target on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Zacks Research cut shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Guggenheim started coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, X4 Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $28.88.

X4 Pharmaceuticals Stock Up 3.0%

Shares of NASDAQ XFOR opened at $4.17 on Friday. The firm has a market cap of $379.14 million, a PE ratio of -0.96 and a beta of 0.43. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $9.56. The company’s fifty day simple moving average is $3.66 and its 200 day simple moving average is $3.62. The company has a quick ratio of 5.48, a current ratio of 10.16 and a debt-to-equity ratio of 0.41.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XFOR. Kingdon Capital Management L.L.C. increased its position in shares of X4 Pharmaceuticals by 300.0% during the third quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock worth $3,192,000 after acquiring an additional 700,000 shares in the last quarter. Rosalind Advisors Inc. acquired a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth about $5,283,000. Palumbo Wealth Management LLC bought a new position in X4 Pharmaceuticals in the 3rd quarter valued at about $326,000. Virtu Financial LLC acquired a new position in X4 Pharmaceuticals during the 4th quarter valued at about $90,000. Finally, Stifel Financial Corp bought a new stake in X4 Pharmaceuticals during the 4th quarter worth approximately $82,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.